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Hepatic mRNA levels of insulin-like growth factor I (IGF I) and of the fetal, nonglycosylated 32 kDa IGF-binding pro- 
tein (BP) were analysed in diabetic, diabetic insulin- and IGF I-treated rats as well as in age-matched, healthy control 
animals. IGF I mRNA levels are reduced in diabetic rats and increased by insulin treatment. In contrast, the infusion 
of IGF I does not significantly upregulate IGF I mRNA levels. Fetal IGF BP mRNA expression is very low in healthy 
control animals, but high levels are found in diabetic rats. Insulin therapy lowers fetal IGF BP mRNA levels, whereas 
IGF I has no effect. We propose that insulin is a major regulator of the 32 kDa IGF BP levels in adult rats. 
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1. INTRODUCTION 
Insulin-like growth factor I, a structural 
homologue of insulin, exerts growth-promoting 
activities in vitro and in vivo [ 1,2]. IGF I circulates 
in plasma tightly associated with high-affinity 
binding proteins [3,4]. Serum IGF I concentrations 
are strongly correlated with growth indices [5]. In 
streptozotocin-diabetic rats, growth is arrested and 
serum IGF I levels are markedly diminished [6,7]. 
The reduction of IGF I levels is accompanied by 
reduced binding protein levels [8]. This reduction 
of total binding capacity of serum is associated 
with a qualitative change of the pattern of binding 
proteins. The glycosylated forms with apparent 
molecular masses of 42-49 kDa, which are the 
predominant species in serum of control animals, 
virtually disappear, whereas the nonglycosylated, 
fetal, 32 kDa ,binding protein is more prominent 
(fig.6 in [8]). Treatment of diabetic rats with IGF 
I or insulin stimulates growth and increases erum 
IGF I levels [5-71. The predominant production 
site of circulating IGF I appears to be the liver 
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[9, lo]. In addition, the liver might also produce the 
fetal binding protein in adult rats [lo], however, 
nothing is known about its regulation. Recently, 
the cDNA of the fetal IGF BP has been cloned 
[ 11,121. Therefore, we examined the hepatic 
mRNA expression of IGF I and of the fetal IGF 
BP in an animal model system consisting of 
healthy control, diabetic and insulin- or IGF I- 
treated diabetic rats. 
2. MATERIALS AND METHODS 
2.1. Animals 
Two strains of rats were used in separate groups of ex- 
periments: (i) Outbred Zur : SIV (Institut fur Zuchthygiene, 
Universitiit Zurich) and (ii) inbred DA(RTla) purchased from 
the Zentralinstitut fur Zuchthygiene, Hannover). Final body 
weight of outbred rats was 400 g, that of inbred rats being 
200-230 g. All experiments were performed with both strains 
and the same qualitative results were obtained. To induce 
diabetes, 4-week-old inbred and outbred rats fasted for 24 h 
were injected iv. with a dose of 80 or 100 mg/kg, respectively 
of streptozotocin (ZanosarR, Upjohn, Kalamazoo, MI). The 
body weight was recorded daily for 3 weeks and rats which con- 
tinued to gain weight were excluded from further experiments. 
Diabetic rats were treated with 6 U/day of insulin (Pro- 
taphanR, HM, Novo) using the NovoPen II or 3OOpg/day of 
recombinant human IGF I (gift from W.R. Rutter, Chiron, 
Emeryville, CA) and J. Nuesch, Ciba-Geigy, Basel). IGF I was 
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dissolved in 0.1 M acetic acid and 0.9% saline and applied S.C. 
using Miniosmotic pumps (Alzet 2001). Diabetic control rats 
were treated in the same way, except hat the pumps were filled 
only with acetic acid and saline. Age-matched, healthy rats 
served as controls. After 7 days of treatment, the rats were kill- 
ed by aorta puncture in deep anesthesia (2 ml/kg Innovar-VetR, 
Pitman-Moore, Washington, USA) and 1 g liver was im- 
mediately processed for RNA extraction. 
2.2. Deiermination of blood glucose, insulin and IGF I 
Blood glucose was determined immediately after aorta punc- 
ture using a YSI glucose analyser. Serum insulin was deter- 
mined using a radioimmunoassay kit (NovoBiolabs, Bagsvaerd, 
Denmark). Immunoreactive IGF I was determined as in [8] us- 
ing human IGF I and rat IGF I (gift from M. Kobayashi, Osaka 
(131) as standards. 
2.3. mRNA isolation and Northern blotting 
Total liver mRNA was isolated using a standard guanidine 
hydrochloride extraction procedure [14]. Samples containing 
20 pg total RNA were separated in a 1% agarose gel containing 
2 M formaldehyde [15] and subsequently subjected to partial 
alkaline hydrolysis. RNA was neutralised and transferred to 
nitrocellulose (Schleicher and Schuell). 
2.4. DNA labeling and hybridization 
Isolated DNA fragments containing IGF I were labeled with 
5-[cu-“Pldeoxycytidine (Amersham) to a specific activity of 
l-4 x 10’ cpm/pg using a random primed DNA labeling kit 
from Boehringer (Mannheim). Hybridization [15] was perform- 
ed at 42°C using 2 x 10’ cpm/ml of a labeled probe. The filter 
was washed at 55°C in 0.2 x SSC and 0.1% SDS for 1 h with 
3 changes. Labeled bands were visualised by autoradiography 
using Kodak X-Omat AR films in the presence of a Cronex 
lightning plus enhancer screen. The intensity of bands was 
determined using a Bio-Rad video densitometer (model 620). 
Hybridisation for fetal BP mRNA was performed as in [12]. 
3. RESULTS AND DISCUSSION 
3.1. Metabolic parameters 
Streptozotocin-treated animals were severely 
diabetic and stopped gaining weight. Respective 
growth and metabolic parameters of a typical ex- 
periment using inbred rats are summarized in table 
1. The average weights at the beginning and end of 
the treatment period with insulin or IGF I are listed 
whereas glucose, insulin and IGF I levels were 
determined at the end of the treatment period. 
Diabetic animals were characterised by very high 
glucose levels, low insulin and IGF I levels and 
complete growth arrest. Insulin treatment lowered 
blood glucose, increased IGF I levels and 
stimulated weight gain. The blood glucose was 
even lower than in controls because the diabetic 
rats had received a bolus injection of insulin only 
2 h prior to being killed. IGF I-treated animals re- 
mained severely diabetic and had high blood 
glucose and low insulin levels, but nevertheless 
gained weight. IGF I serum levels in IGF I-treated 
animals are difficult to interpret, since these 
animals contain a mixture of residual rat and in- 
fused human IGF I, whereas the standards used in 
the immunoassay were either rat or human IGF I. 
We do not believe that this poses a real problem, 
since IGF I values observed were well above those 
of healthy controls with either rat or human IGF 
I as standard. Age-matched, healthy control rats 
do not gain weight during the treatment period, 
because they have already reached their final body 
weight during the period between the administra- 
tion of streptozotocin and the beginning of treat- 
ment of diabetic rats. Very similar results were 
obtained with outbred rats except that age- 
matched healthy controls (final body weight 400 g) 
continued to grow during the whole period of the 
experiment. 
3.2. Hepatic IGF I mRNA levels 
Total hepatic RNA was analysed by Northern 
blotting. A representative gel of IGF I mRNA of 
a few outbred animals is shown in fig.1. The most 
prominent band seen migrates at 8 kb, and in addi- 
Table 1 
Metabolic and growth parameters determined from control, diabetic, insulin-treated and IGF I-treated 
diabetic rats 
Initial weight End weight Glucose Insulin IGF I (h) IGF I (r) 
(9) (9) (mmol/l) (ng/ml) (ng/ml) (ng/ml) 
Controls 196+ 8 205 * 7.1 7.0 + 0.3 0.94 + 0.17 180 + 18 1235 t 171 
Diabetic 134 + 11 135 & 4.6 21.9 + 1.7 0.34 f 0.05 56 * 7.3 413 * 85 
Diabetic (ins) 131 + 11 171 & 8.3 2.95 * 1.8 >lO 146 + 12 885 + 138 
Diabetic (IGF) 128 + 7.4 149 + 16.2 22.2 + 2 0.28 + 0.04 446 * 100 3073 & 991 
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Fig.1. Northern blot of liver IGF I mRNA from control, 
diabetic, insulin-treated and IGF I-treated diabetic rats. Age- 
matched, healthy rats (control), streptozotocin-diabetic rats 
(diabetic), insulin-treated, diabetic rats (insulin) and IGF I- 
treated diabetic rats (IGF I) were analysed for the presence of 
hepatic IGF I mRNA as described in section 2. 
tion there are minor bands of 2 kb and a broad 
band of l-l .5 kb. The predominance of the large 
8 kb message indicates that the RNA isolates were 
highly intact. Previous authors also reported the 
appearance of several messages, the smaller ones, 
however, being more abundant [ 16,171. We did not 
observe more than lo-15% of the total IGF I 
mRNA as low molecular mass species. 
Fig.2 shows a quantitative estimate of liver IGF 
I mRNA and serum IGF I levels in an experiment 
with outbred animals. In order to compare hepatic 
IGF I mRNA and IGF I serum levels six animals 
were used per group. Values of healthy controls 
were taken as 100% and all other experimental 
groups were expressed as % of control. In this 
group of animals growth restoration by insulin 
treatment was 77% and by IGF I 57% when com- 
pared to healthy control rats. In agreement with 
previous studies, insulin treatment resulted in an 
increase of serum IGF I concentrations [5]. There 
was a correlation between serum levels of IGF I 
and hepatic IGF I mRNA levels in diabetic as well 
as in insulin-treated diabetic animals. In IGF I- 
treated rats serum IGF I concentrations were very 
200 
control diabetic insu/in IGF -I 
Fig.2. Comparison of relative levels of liver IGF I mRNA and 
IGF I in serum from healthy control, diabetic, insulin-treated 
and IGF I-treated diabetic rats. IGF I mRNA levels (hatched 
bars) and serum IGF I levels (unfilled bars) were determined in 
age-matched, healthy rats (control), diabetic rats (diabetic), 
insulin-treated (insulin) and IGF I-treated (IGF I) diabetic rats. 
Means and SD were determined from 6 animals and values of 
controls were taken as 100%. Values derived from other 
experimental groups were expressed as % of control. 
high but there was no significant increase of IGF 
I mRNA when compared to the diabetic group. 
These results further emphasize that the liver is the 
major source of IGF I in serum and that serum 
levels are regulated via regulation of IGF I mRNA 
in the liver. In contrast to insulin, IGF I infusions 
do not significantly affect hepatic IGF I mRNA 
levels and, hence, endogenous IGF I does not 
mimic the effects of insulin at that level. Growth 
restoration by infused IGF I must, therefore, result 
from a direct effect of infused IGF I on target 
organs. 
3.3. Hepatic fetal IGF BP mRNA levels 
Hepatic mRNA was further probed for the 
presence of the fetal IGF binding protein message. 
The upper part of fig.3 shows a typical Northern 
blot for a selection of a few animals. A single 
mRNA species of length 1.6 kb is observed. The 
lower part of fig.3 demonstrates quantitation of 
the respective signal. In healthy inbred rats we 
observed only a very small amount of fetal IGF- 
binding protein mRNA (see fig.3) whereas no 
message was detectable with RNA of outbred rats 
(not shown). In contrast, in diabetic animals of 
both rat strains there was a large increase in fetal 
IGF BP mRNA levels, that was again brought 
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Fig.3. Northern blot of hepatic fetal IGF BP RNA. Age- 
matched, healthy rats (controls), streptozotocin-diabetic rats 
(diabetic), insulin-treated (insulin) and IGF I-treated (IGF I) 
diabetic rats were analysed for the presence of hepatic fetal BP 
mRNA. (Upper) Northern blot and (lower) relative absorbances 
of the bands. 
back to normal by insulin treatment. In contrast, 
the infusion of IGF I did not reduce fetal IGF BP 
message in diabetic animals. These results show 
that in situations where insulin concentrations are 
low (diabetic rats, IGF I-treated diabetic rats) fetal 
BP mRNA levels are high, whereas in situations 
where insulin levels are high (healthy rats, insulin- 
treated diabetic rats) this mRNA species is very 
rare. Therefore, we conclude that insulin in vivo 
either directly or via insulin mediated mechanisms 
such as growth hormone induction, regulates fetal 
IGF BP expression. Recent in vitro results derived 
from isolated hepatocytes upport the notion that 
insulin has a direct effect on the mRNA level of the 
fetal IGF BP (in preparation). 
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